The oncogenic effect of mutations in the fusion genes such as ARID1A, PVT1, GFI1, MYCN, DNMT1, and TET3 has been identified in various tumors including medulloblastomas to regulate tumorigenesis (Bell et al., 2010; Northcott et al., 2014; Mathur, 2018; Mo et al., 2020; Onagoruwa et al., 2020; Wong, 2020), suggesting that the predicted inframe fusion proteins may possess oncogenic potential. This evidence concerns the gene PVT1 and medulloblastoma.